Macquarie Group’s Novartis NVS Stock Holding History

Macquarie Group’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-141,577	Closed	-$15.1M	–	1835
2024 Q2	$15.1M	Sell	141,577 -240,209	-63%	-$24.1M	0.02%	720
2024 Q1	$36.9M	Sell	381,786 -52,289	-12%	-$5.36M	0.04%	517
2023 Q4	$43.8M	Sell	434,075 -214,378	-33%	-$20.7M	0.05%	465
2023 Q3	$66.1M	Sell	648,453 -11,828	-2%	-$1.2M	0.08%	322
2023 Q2	$66.6M	Sell	660,281 -13,046	-2%	-$1.3M	0.08%	340
2023 Q1	$61.9M	Sell	673,327 -12,839	-2%	-$1.12M	0.07%	346
2022 Q4	$62.2M	Sell	686,166 -114,468	-14%	-$9.64M	0.07%	366
2022 Q3	$60.9M	Sell	800,634 -17,012	-2%	-$1.41M	0.07%	363
2022 Q2	$69.1M	Sell	817,646 -18,139	-2%	-$1.59M	0.08%	351
2022 Q1	$73.3K	Buy	835,785 +29,415	+4%	+$2.55M	0.06%	395
2021 Q4	$70.5M	Buy	806,370 +27,520	+4%	+$2.28M	0.06%	413
2021 Q3	$63.7M	Sell	778,850 -5,478	-0.7%	-$493K	0.05%	450
2021 Q2	$71.6M	Buy	784,328 +67,092	+9%	+$5.97M	0.06%	411
2021 Q1	$61.3M	Buy	717,236 +111,204	+18%	+$9.98M	0.09%	287
2020 Q4	$57.2M	Sell	606,032 -24,286	-4%	-$2.12M	0.08%	283
2020 Q3	$54.8M	Sell	630,318 -35,156	-5%	-$3.05M	0.09%	238
2020 Q2	$58.1M	Sell	665,474 -169,360	-20%	-$14.6M	0.1%	225
2020 Q1	$68.8M	Sell	834,834 -33,699	-4%	-$3.01M	0.14%	140
2019 Q4	$82.2M	Sell	868,533 -8,143	-0.9%	-$731K	0.12%	162
2019 Q3	$76.2M	Sell	876,676 -24,463	-3%	-$2.2M	0.13%	151
2019 Q2	$82.3M	Sell	901,139 -115,312	-11%	-$9.76M	0.14%	140
2019 Q1	$87.6M	Sell	1,016,451 -14,769	-1%	-$1.19M	0.15%	120
2018 Q4	$79.3M	Sell	1,031,220 -9,324	-0.9%	-$726K	0.15%	117
2018 Q3	$80.3M	Sell	1,040,544 -38,558	-4%	-$2.85M	0.13%	145
2018 Q2	$73M	Sell	1,079,102 -10,803	-1%	-$745K	0.13%	150
2018 Q1	$79M	Sell	1,089,905 -193,732	-15%	-$14.7M	0.14%	132
2017 Q4	$96.6M	Sell	1,283,637 -16,159	-1%	-$1.22M	0.17%	102
2017 Q3	$100M	Sell	1,299,796 -5,876	-0.5%	-$444K	0.18%	104
2017 Q2	$97.7M	Buy	1,305,672 +193,143	+17%	+$13.7M	0.18%	91
2017 Q1	$74M	Buy	1,112,529 +18,236	+2%	+$1.22M	0.13%	125
2016 Q4	$71.4M	Sell	1,094,293 -524,273	-32%	-$34M	0.14%	120
2016 Q3	$115M	Sell	1,618,566 -1,720,388	-52%	-$125M	0.22%	81
2016 Q2	$247M	Buy	3,338,954 +1,730,426	+108%	+$120M	0.24%	81
2016 Q1	$104M	Buy	1,608,528 +55,403	+4%	+$3.77M	0.21%	90
2015 Q4	$120M	Sell	1,553,125 -304,694	-16%	-$24.2M	0.25%	80
2015 Q3	$153M	Buy	1,857,819 +20,750	+1%	+$1.85M	0.33%	65
2015 Q2	$162M	Sell	1,837,069 -250,313	-12%	-$23M	0.32%	72
2015 Q1	$184M	Sell	2,087,382 -31,027	-1%	-$2.75M	0.36%	62
2014 Q4	$176M	Sell	2,118,409 -158,561	-7%	-$13.1M	0.36%	60
2014 Q3	$192M	Sell	2,276,970 -165,520	-7%	-$13.4M	0.41%	60
2014 Q2	$198M	Buy	2,442,490 +159,709	+7%	+$12.6M	0.44%	57
2014 Q1	$174M	Buy	2,282,781 +67,244	+3%	+$4.9M	0.3%	81
2013 Q4	$160M	Buy	2,215,537 +96,180	+5%	+$6.69M	0.29%	81
2013 Q3	$146M	Sell	2,119,357 -18,940	-0.9%	-$1.25M	0.28%	84
2013 Q2	$135M	Buy	+2,138,297	New	+$139M	0.3%	81

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group's NVS Position: Q3 2024 in Review

Macquarie Group sold out of Novartis (NVS) in Q3 2024, closing a stake of 141,577 shares — an estimated $15.1M sold.

Macquarie Group first reported a position in NVS in Q2 2013 and held it in 45 quarters. The position peaked at $247M in Q2 2016. 1,311 funds tracked by Wall St. Rank hold NVS as of Q3 2024.

Macquarie Group reported no remaining Novartis position as of Q3 2024 after selling out during the quarter.
Macquarie Group sold 141,577 Novartis shares in Q3 2024, an estimated $15.1M.
Macquarie Group first reported a position in Novartis in Q2 2013 and held it in 45 quarters.
Macquarie Group's Novartis position peaked at $247M in Q2 2016.
1,311 funds tracked by Wall St. Rank held Novartis as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.